Do analysts rate PRTC or KLRS?

Kalaris Therapeutics has a consensus price target of $15.60, indicating a potential upside of 260.28%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kalaris Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has stronger valuation and earnings, PRTC or KLRS?

Kalaris Therapeutics has lower revenue, but higher earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.15 N/A

Is PRTC or KLRS more profitable?

PureTech Health's return on equity of 0.00% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PureTech Health N/A N/A N/A Kalaris Therapeutics N/A -72.78% -43.49%

Does the media prefer PRTC or KLRS?

In the previous week, Kalaris Therapeutics had 2 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Kalaris Therapeutics and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 1.49 beat Kalaris Therapeutics' score of 0.42 indicating that PureTech Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KLRS or EOLS?

In the previous week, Kalaris Therapeutics and Kalaris Therapeutics both had 3 articles in the media. Evolus' average media sentiment score of 0.94 beat Kalaris Therapeutics' score of 0.42 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Evolus 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, KLRS or ANL?

Adlai Nortye has higher revenue and earnings than Kalaris Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kalaris Therapeutics N/A N/A -$43.44M -$2.15 N/A Adlai Nortye $5M 82.56 -$35.53M N/A N/A

Is KLRS or ANL more profitable?

Adlai Nortye's return on equity of 0.00% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -72.78% -43.49% Adlai Nortye N/A N/A N/A

Do analysts recommend INDP or KLRS?

Kalaris Therapeutics has a consensus price target of $15.60, indicating a potential upside of 260.28%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has higher valuation & earnings, INDP or KLRS?

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.15 N/A

Is INDP or KLRS more profitable?

Kalaris Therapeutics' return on equity of -72.78% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -1,030.07% -299.69% Kalaris Therapeutics N/A -72.78% -43.49%

Kalaris Therapeutics (KLRS) Competitors

$4.33 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$4.42 +0.09 (+2.06%)

As of 06/12/2026 05:44 PM Eastern

Compare

KLRS vs. PRTC, EOLS, ANL, INDP, and KMDA

Should you buy Kalaris Therapeutics stock or one of its competitors? MarketBeat compares Kalaris Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kalaris Therapeutics include PureTech Health (PRTC), Evolus (EOLS), Adlai Nortye (ANL), Indaptus Therapeutics (INDP), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry.

How does Kalaris Therapeutics compare to PureTech Health?

PureTech Health (NASDAQ:PRTC) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

0.0% of PureTech Health shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 5.3% of PureTech Health shares are held by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kalaris Therapeutics has lower revenue, but higher earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

Kalaris Therapeutics has a consensus price target of $15.60, indicating a potential upside of 260.28%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kalaris Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

PureTech Health's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Kalaris Therapeutics	N/A	-72.78%	-43.49%

PureTech Health has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.15, suggesting that its share price is 85% less volatile than the broader market.

In the previous week, Kalaris Therapeutics had 2 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Kalaris Therapeutics and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 1.49 beat Kalaris Therapeutics' score of 0.42 indicating that PureTech Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kalaris Therapeutics beats PureTech Health on 8 of the 13 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Evolus?

Kalaris Therapeutics (NASDAQ:KLRS) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Kalaris Therapeutics has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Evolus	$297.18M	1.49	-$51.64M	-$0.67	N/A

Kalaris Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the broader market. Comparatively, Evolus has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

Kalaris Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Evolus	-14.39%	N/A	-19.03%

In the previous week, Kalaris Therapeutics and Kalaris Therapeutics both had 3 articles in the media. Evolus' average media sentiment score of 0.94 beat Kalaris Therapeutics' score of 0.42 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evolus	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kalaris Therapeutics currently has a consensus price target of $15.60, indicating a potential upside of 260.28%. Evolus has a consensus price target of $16.00, indicating a potential upside of 137.74%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Kalaris Therapeutics is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Kalaris Therapeutics beats Evolus on 8 of the 15 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Adlai Nortye?

Kalaris Therapeutics (NASDAQ:KLRS) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Adlai Nortye has higher revenue and earnings than Kalaris Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Adlai Nortye	$5M	82.56	-$35.53M	N/A	N/A

Kalaris Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Adlai Nortye's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Adlai Nortye	N/A	N/A	N/A

In the previous week, Kalaris Therapeutics had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 3 mentions for Kalaris Therapeutics and 1 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.87 beat Kalaris Therapeutics' score of 0.42 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Overall Sentiment
Kalaris Therapeutics	Neutral
Adlai Nortye	Very Positive

Kalaris Therapeutics currently has a consensus price target of $15.60, indicating a potential upside of 260.28%. Adlai Nortye has a consensus price target of $24.25, indicating a potential upside of 134.98%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Kalaris Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Kalaris Therapeutics beats Adlai Nortye on 7 of the 13 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Kalaris Therapeutics' return on equity of -72.78% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
Kalaris Therapeutics	N/A	-72.78%	-43.49%

In the previous week, Kalaris Therapeutics had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 3 mentions for Kalaris Therapeutics and 2 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.44 beat Kalaris Therapeutics' score of 0.42 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Indaptus Therapeutics	Positive
Kalaris Therapeutics	Neutral

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

Kalaris Therapeutics has a consensus price target of $15.60, indicating a potential upside of 260.28%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Indaptus Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market.

7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 23.6% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Kalaris Therapeutics beats Indaptus Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Kamada?

Kamada (NASDAQ:KMDA) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Kamada has a net margin of 11.21% compared to Kalaris Therapeutics' net margin of 0.00%. Kamada's return on equity of 7.73% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Kalaris Therapeutics	N/A	-72.78%	-43.49%

In the previous week, Kalaris Therapeutics had 2 more articles in the media than Kamada. MarketBeat recorded 3 mentions for Kalaris Therapeutics and 1 mentions for Kamada. Kamada's average media sentiment score of 1.87 beat Kalaris Therapeutics' score of 0.42 indicating that Kamada is being referred to more favorably in the media.

Company	Overall Sentiment
Kamada	Very Positive
Kalaris Therapeutics	Neutral

Kamada presently has a consensus target price of $12.00, indicating a potential upside of 61.29%. Kalaris Therapeutics has a consensus target price of $15.60, indicating a potential upside of 260.28%. Given Kalaris Therapeutics' higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Kamada has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market.

Kamada has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.37	$20.20M	$0.35	21.26
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

20.4% of Kamada shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Kamada beats Kalaris Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Kalaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRS vs. The Competition

Export

Metric	Kalaris Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$103.01M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-2.01	20.00	24.00	24.42
Price / Sales	N/A	306.76	515.84	118.72
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	1.03	8.32	10.60	6.82
Net Income	-$43.44M	$23.94M	$3.57B	$337.56M
7 Day Performance	3.84%	1.84%	0.59%	1.16%
1 Month Performance	-11.63%	-0.04%	1.54%	3.16%
1 Year Performance	64.02%	44.82%	25.41%	30.60%

Kalaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRS Kalaris Therapeutics	4.111 of 5 stars	$4.33 flat	$15.60 +260.3%	+64.0%	$103.01M	N/A	N/A	110	News Coverage Analyst Downgrade
PRTC PureTech Health	0.7157 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100	Positive News
EOLS Evolus	2.5365 of 5 stars	$6.42 -2.8%	$16.00 +149.4%	-32.2%	$422.46M	$301.79M	N/A	170	News Coverage Gap Down
ANL Adlai Nortye	2.1946 of 5 stars	$10.50 -4.6%	$24.25 +131.1%	+512.5%	$419.80M	$5M	N/A	127	Gap Up
INDP Indaptus Therapeutics	1.2966 of 5 stars	$3.60 -24.3%	N/A	-60.6%	$417.40M	N/A	N/A	6	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRS) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. PRTC, EOLS, ANL, INDP, and KMDA

How does Kalaris Therapeutics compare to PureTech Health?

Summary

How does Kalaris Therapeutics compare to Evolus?

Summary

How does Kalaris Therapeutics compare to Adlai Nortye?

Summary

How does Kalaris Therapeutics compare to Indaptus Therapeutics?

Summary

How does Kalaris Therapeutics compare to Kamada?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. PRTC, EOLS, ANL, INDP, and KMDA

How does Kalaris Therapeutics compare to PureTech Health?

Do insiders & institutionals hold more shares of PRTC or KLRS?

Which has stronger valuation and earnings, PRTC or KLRS?

Do analysts rate PRTC or KLRS?

Is PRTC or KLRS more profitable?

Which has more volatility & risk, PRTC or KLRS?

Does the media prefer PRTC or KLRS?

Summary

How does Kalaris Therapeutics compare to Evolus?

Which has stronger earnings and valuation, KLRS or EOLS?

Which has more volatility and risk, KLRS or EOLS?

Is KLRS or EOLS more profitable?

Does the media refer more to KLRS or EOLS?

Do analysts rate KLRS or EOLS?

Do institutionals & insiders believe in KLRS or EOLS?

Summary

How does Kalaris Therapeutics compare to Adlai Nortye?

Which has stronger earnings and valuation, KLRS or ANL?

Which has more volatility and risk, KLRS or ANL?

Is KLRS or ANL more profitable?

Does the media refer more to KLRS or ANL?

Do analysts rate KLRS or ANL?

Do institutionals & insiders believe in KLRS or ANL?

Summary

How does Kalaris Therapeutics compare to Indaptus Therapeutics?

Is INDP or KLRS more profitable?

Does the media prefer INDP or KLRS?

Which has higher valuation & earnings, INDP or KLRS?

Do analysts recommend INDP or KLRS?

Which has more risk and volatility, INDP or KLRS?

Do insiders and institutionals believe in INDP or KLRS?

Summary

How does Kalaris Therapeutics compare to Kamada?

Is KMDA or KLRS more profitable?

Does the media prefer KMDA or KLRS?

Do analysts recommend KMDA or KLRS?

Which has more volatility and risk, KMDA or KLRS?

Which has preferable earnings and valuation, KMDA or KLRS?

Do institutionals & insiders believe in KMDA or KLRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools